By Florence Wallace,2014-06-26 21:26
6 views 0


    Centre for Molecular Oncology and Imaging

    Chair in Male Genitourinary Oncology (Clinical Oncology)

    Clinical Professor/Honorary Consultant

    (Ref: 09390/MB)

    Applications are invited for a Chair in Male Genitourinary Oncology, based at the Institute of Cancer at Barts and

    the London School of Medicine and Dentistry, primarily at the School‟s Charterhouse Square campus and at St

    Bartholomew‟s Hospital.

    This is an exciting opportunity for a senior clinical academic to develop and lead a research programme in male

    genitourinary oncology with funding (?1M) from the Orchid Charity and Barts & The London Charity, as well as a

    substantial, flexible package of support from the School of Medicine and NHS Trust. The appointee will be able

    to appoint a Clinical Senior Lecturer/Honorary Consultant in Clinical Oncology and other staff in support of their

    clinical and research activities. The Centre has existing programmes of research into the molecular genetics, cell

    biology and gene therapy of prostate cancer, as well as an expanding clinical trials portfolio for genitourinary


    The Cancer Clinical Academic Unit will move into outstanding new facilities at Barts Hospital in March 2010,

    including state of the art equipment for radiotherapy with IMRT/IGRT capability.

    The appointee must be accredited in Clinical Oncology (Radiation Oncology) and will be offered an Honorary

    Consultant contract with the Barts and The London NHS Trust. The post-holder will have a PhD or MD and will

    be expected to acquire further resources and financial support in order to develop and direct an independent

    research programme into male genitourinary cancers, complementary to the overall research strategy of the

    Centre, Institute and School, and of the Trust‟s Cancer Clinical Academic Unit. This is a full time (10 Programmed Activities), permanent appointment.

Salary is commensurate with the Clinical Professor Scale (HCC) dependent on seniority and experience. The

    benefits package for this post includes 30 days leave plus 4 College closure days, flexible working hours,

    childcare vouchers scheme, contributory final salary pension scheme and an interest free season ticket loan.

    This appointment is subject to an enhanced Criminal Records Bureau (CRB) check.

Candidates must be able to demonstrate their eligibility to work in the UK in accordance with the Immigration,

    Asylum and Nationality Act 2006. Where required this may include entry clearance or continued leave to remain

    under the Points Based Immigration Scheme.

Informal enquiries about this post can be made to the Director of the Institute of Cancer and the Trust‟s Clinical

    Academic Unit in Cancer, Professor Nick Lemoine ( Details about the Institute of Cancer, can be found on Further details and an application form can be found at

Completed application forms, quoting 09390/MB, should be returned by email to

    or by post to: Charterhouse Square Recruitment, Barts & The London School of Medicine & Dentistry,

    c/o SMD Management Offices, The Lodge House, Charterhouse Square, London, EC1M 6BQ.

    thThe closing date for the applications is 12 noon (BST) on 11 December 2009.

    Valuing Diversity & Committed to Equality


Job Title: Chair in Male Genitourinary Oncology (Clinical Oncology)

     Clinical Professor/Honorary Consultant

Institute: Cancer

    Centre: Molecular Oncology & Imaging Grade: Clinical Professor (Honorary Clinical Consultant)

    Type of Academic Contract: Principal Investigator (see Appendix C)

Hours: Full-time

    Appointment period: Permanent

    Probationary period: N/A

    Main Location: Currently based at the Institute of Cancer at Charterhouse Square and

    at St Bartholomew‟s Hospital. The postholder may also be required to

    carry out duties on other College/Hospital sites.

1. Accountability

? The postholder is managerially accountable to the Institute Director (DoI).

    ? The postholder is accountable to the Centre Lead and DoI for the research elements of the post.

    ? The postholder is accountable to the Clinical Director and General Manager of the Trust‟s Cancer Clinical Academic Unit for the provision of clinical services, and for associated managerial and

    administrative functions. The postholder will observe all appropriate Trust policies, protocols and

    procedures whilst undertaking clinical work with Trust patients and patient materials.

2. Job purpose

    ? To demonstrate significant intellectual leadership, providing encouragement and guidance to

    other senior and junior members of staff, in particular directing and managing a team in male

    genitourinary cancer research

    ? To undertake and direct high level translational („bench-to-bedside‟) research into the

    pathogenesis, progression and/or therapy of male genitourinary malignancies complementary to

    the overall research strategy of the Centre, Institute and School, and of the Trust‟s Cancer

    Academic Unit.

    ? To contribute to the delivery of clinical service within the Trust Cancer Academic Unit.

    ? To undertake such administrative, managerial and other duties as are reasonably to be expected

    of a senior member of clinical academic staff, as agreed with the Centre Lead and DoI.

3. Summary of post

? The postholder has an honorary consultant contract with Barts and The London Trust (see

    Appendix B)

    ? The post sits within the Centre for Molecular Oncology & Imaging, part of the School‟s Institute of

    Cancer (see Appendix A) for the laboratory research and in the Centre for Experimental Cancer

    Medicine for clinical trials.

    ? The appointment is jointly funded by the Orchid charity, Barts and The London Charity and Barts

    and the London NHS Trust.


? The postholder will undertake six academic programmed activities on behalf of the School and

    four clinical programmed activities on behalf of the Trust.

4. Duties of the post

A. Clinical Duties (4 Programmed Activities)

The postholder is required to have and maintain full registration with the General Medical Council.

    Medical Staff are advised to continue membership of one of the medical defence organisations. An

    honorary consultant contract is in place for Barts and The London NHS Trust.

? To undertake two weekly urological oncology clinics at Barts & The London NHS Trust that will

    involve joint consultations with the Medical Oncologists and Urological Surgeons. ? To undertake the planning and supervision of radiotherapy for urological cancer.

    ? To contribute to the supervision of systemic therapy for urological cancer.

    ? To participate fully as member of the multi-disciplinary team in urological cancer.

    ? To assist in the development and evaluation of new procedures and keep appropriate records of

    data obtained, in accordance with the requirements of the Ethics Committee and the Data

    Protection Act.

    Clinical Governance:

    ? The postholder must have an awareness and understanding of clinical governance issues, and is

    expected to participate in Clinical Governance activities related to their clinical work. The post

    holder is expected to participate in the Trust‟s clinical effectiveness activities, and to encourage

    and foster improvements in the quality and standards of clinical services. The post-holder will

    assist with the safeguarding of high standards of care by participating in the creation of an

    environment in which excellence in clinical care will flourish.

    ? The postholder is required to participate fully in the joint College/Trust appraisal process and to

    maintain an appropriate portfolio of work activities for revalidation purposes.

Continuing Professional Development and Continuing Medical Education:

    ? The post holder is expected to take responsibility for their own Continuing Professional

    Development and take part in Continuing Medical Education activities, in line with the

    requirements of the Royal College of Radiologists guidelines.

    ? The post-holder must be committed to the concept of lifelong learning and produce and maintain

    a Personal Development Plan in agreement with their Head of Service. Continuing medical

    education is essential: time and financial support from the Trust is available for participation in


    ? Study leave is available under the Terms and Conditions of Service for Hospital Medical and

    Dental staff, subject to the approval of the Head of Service.

Teaching and Training:

    ? The Trust is committed to sustaining and advancing the provision of medical, dental, nursing and

    other professional education and to the delivery of high quality postgraduate and undergraduate


    ? As part of their clinical supporting programmed activities, the post-holder is expected to

    participate fully in the teaching and training of junior staff in medical oncology, especially in

    translational research, visiting research fellows (including from overseas) and those undertaking

    higher degrees. For the majority of Consultants this will involve specific timetables and regular

    teaching commitments agreed with the Head of Service, and supervised by the Unit Training

    Director and Educational Supervisors. There is a regional postgraduate training scheme rotation

    based at the Barts & The London NHS Trust.

    ? The post holder will also be expected to assist in the training of nursing and other staff as



General Information:

    ? The post holder is expected to work closely with the Service Manager and the Head of Service in

    the management and administration of resources and to be active in promoting changes that

    improve the delivery of service to patients.

    ? An office, personal computer (with internet access), secretarial support and other facilities,

    including access to current books and journals is provided.

Health and Safety:

    ? The post holder is expected to undertake the appropriate management responsibilities, and be

    aware of individual responsibilities in accordance with the Trust‟s Health and Safety policy and

    report as necessary, any untoward accident, incident or potentially hazardous environment. The

    post holder will promote and implement the Health and Safety Policy. The Trust operates a No

    Smoking Policy.

B. Academic (6 Programmed Activities)

Research: Research productivity will be assessed according to the School‟s performance standards

    for academic staff (see Appendix C).

    ? To acquire resources and financial support in order to develop and direct an independent

    research programme into male urological cancers (particularly prostate cancer), complementary

    to the overall research strategy of the Centre, Institute and School, and of the Trust Cancer

    Clinical Academic Unit.

    ? To demonstrate significant intellectual leadership, directing and managing a team in male

    genitourinary cancer research, including both laboratory research and clinical trials. ? To develop and maintain national and international research links and a high profile in the subject

    or field, e.g. by attending and presenting at national and international conferences. ? To publish research results using well-regarded means, such as high impact factor peer-reviewed

    academic journals and conference proceedings.

    ? To play a leading role in the Centre‟s/Institute‟s regular research group meetings, to attend

    laboratory and journal club meetings, weekly seminars, audit meetings, etc. ? To supervise undergraduate and postgraduate students engaged in research, postdoctoral

    research workers and research assistants, clinical and nursing staff in the Centre, as appropriate. ? To ensure that all research is undertaken according to Good Clinical Practice (GCP), Good

    Laboratory Practice (GLP), College and Trust protocols.

    ? Any clinical study proposals must comply with the School‟s and Trust‟s policies and procedures

    and, in particular, must be registered with the School and Trust‟s Joint Research Office. Research

    proposals must be submitted through the School‟s Research Deanery and the Trust‟s Ethics

    Committee, and all costings and overheads agreed in advance with the School and Trust‟s Joint

    Research Office.

Teaching: The postholder‟s contribution to teaching activities will be determined according to the

    School‟s performance standards for academic staff (see Appendix C).

? To contribute to the development and organisation of undergraduate and postgraduate courses.

    ? The School runs a problem-based learning programme and the postholder may be asked to be

    the facilitator to small groups of students. Appropriate training will be given as necessary. ? Responsibility for appraisal of trainees, where appropriate.

    Administration: ? To take responsibility for particular areas of administration as agreed with the Centre Lead/DoI. ? To attend Clinical Strategy Committee meetings as required, as well as those of other relevant

    Institute/School College committees/boards, as agreed with the Centre Lead/DoI. ? To carry out such Centre, School or College administrative tasks as may be required by the Centre



C. Other

    ? The postholder must ensure they are fully aware of and comply with the College‟s/Trust‟s policies

    and procedures in relation to, inter alia, confidentiality, health and safety at work, COSHH

    regulations, infection control, safe handling of drugs, and all local safety rules regarding fire,

    chemical, radioisotope and gene manipulation hazards.

    ? The postholder must at all times carry out their responsibilities with due regard to the College‟s

    and Trust‟s equal opportunities policy.

    ? The postholder must at all times respect the confidentiality of electronically stored personal data

    in line with the requirements of the Data Protection Act.

    ? Due to the nature of the work, this post is exempt from the provision of section 4 (2) of the

    Rehabilitation of offenders Act 1974, by virtue of the Rehabilitation of Offenders Act 1974

    (Exemption Order 1975). Applicants are therefore not entitled to withhold information about

    convictions, including those which, for other purposes are “spent” under the provisions of the Act.

    Failure to disclose such information may result in dismissal or disciplinary action. ? Appointment is subject to satisfactory pre-employment health screening carried out by the Trust

    and College following recommendation for appointment.

    ? The postholder is required to reside not more than 20 miles by road, from Barts and The London

    NHS Trust, unless specific approval is given for a greater distance.

    ? This job description sets out the duties of the post at the time it was drawn up. Such duties may

    vary from time to time without changing the general character of the duties or level of

    responsibility entailed.

    ? The duties of the post outlined above are not exhaustive, and the postholder is expected to be co-

    operative and flexible, undertaking such other duties as may from time to time be reasonably

    expected of a senior member of clinical academic staff in a university.

    ? These duties will be subject to review in line with the changing requirements of the Centre,

    Institute, School, College or Trust, and with the development needs of the postholder as identified

    through regular review/appraisal processes.

5. Current Joint Job Plan

    This is an illustrative job plan, based on the current Urological Oncology service. Although the

    academic and NHS commitments will remain at 6 and 4 PAs respectively, the exact content of the

    job plan will be subject to service development / review and negotiation with the postholder. All job

    plans are reviewed on at least an annual basis.


    No. LocatioDay Time Work Categorisation of n PAs 0900-IoC Academic 2 Monday 1700

    0800-BLT Network Specialist Urology Oncology NHS-DCC 0.75 1100 MDT followed by

    BLT/Homerton/Newham non-

    specialist Urology MDT (all via

    telelink) Tuesday

    1100-BLT Urology Oncology clinic (with NHS-DCC 0.5 1300 surgeons)

    1300-IoC Academic 0.75 1600

    0900-IoC Academic 2 Wednesday 1700

    0900-BLT Urology oncology clinic (Clinical & NHS-DCC 1 1300 Medical Oncologists) + clinical

    administration Thursday

    1300-BLT Radiotherapy planning and on-NHS-DCC 0.75 1700 treatment review. SpR teaching NHS-SPA 0.25 0900-BLT SpR teaching / audit / NHS research NHS-SPA 0.75 1200 Friday 1200-IoC Academic 1.25 1700

     Department and committee meetings; Additional

    On-call cover for junior medical staff agreed

    activity to

    be worked


    NHS Direct Clinical Care 3 NHS Supporting Professional Activities (incl NHS-led research/teaching) 1 Academic (Teaching/Research/Admin) 6



Organisational Chart


     Essential Desirable

     Qualification? MBBS/MBChB or equivalent

    s ? FRCR or equivalent.

    ? CCT in Clinical Oncology or equivalent

    experience and formal training

    ? On, or eligible to be on, the GMC Specialist

    Register in Clinical Oncology

    ? PhD or MD research degree or equivalent 1Previous ? Have satisfied the academic criteria for award of ? Clinical experience in other

    experience academic title of Professor through the University fields of oncology

    of London appointments/promotions procedures. ? Experience of management,

    ? Extensive clinical experience in the care of eg participation in committee

    genitourinary malignancies equivalent to that work

    required to gain UK sub-specialist CCT in clinical


    ? Proven experience in clinical management and

    service development.

    ? An international reputation in research into basic,

    translational or clinical research in male

    genitourinary oncology, with an appropriate peer-

    reviewed publication record

    ? Proven experience in application of research to

    clinical and basic science problems

    ? Have successfully developed their own research

    interests and independent programmes.

    ? Have successfully obtained peer-reviewed grant

    funding for research.

    ? Have a demonstrated ability to provide

    postgraduate supervision.

    ? Proven experience in management of a research

    team, both laboratory research and clinical trials

Special skills ? Have demonstrated an ability to provide ? Computer and IT literacy

    leadership to, as well as to work co-operatively and

    with, colleagues as part of a multi-disciplinary knowledge


    ? Ability to teach medical students and junior

    medical and nursing staff

    ? Knowledge of multidisciplinary clinical audit and

    demonstrable commitment to improving quality of

    care to patients

    ? Ability to manage staff and resources effectively

    ? Ability to communicate effectively with GPs and

     1 University of London Ordinance 16: “Professors: In appointing a person as a Professor or conferring the title of Professor regard shall be had to the person’s national/international standing in the relevant subject or profession as established by outstanding contributions to its advancement through publications, creative work or other appropriate forms of scholarship or performance, and through teaching and administration. .”


    other professionals in hospital and community

    ? Ability to develop research projects and supervise

    trainees in their research

     Personal ? Flexible and co-operative approach to colleagues Qualities ? A demonstrative ability to cope under pressure

    ? Team player with demonstrable leadership


    ? Good communication skills

     Other ? Full GMC Registration

    Requirement? A demonstrable commitment to the School in

    s teaching and research



The Institute of Cancer

The creation of the Institute of Cancer, as part of the School‟s restructuring in 2003, is a key step in

    the establishment of a major international centre of excellence in both cancer research and clinical

    cancer care at the Charterhouse Square Campus (including the West Smithfield site at St

    Bartholomew‟s Hospital). The Institute currently consists of six Research Centres:

? Molecular Oncology & Imaging (Professor Nick Lemoine, Professor Stephen Mather, Professor

    Iain McNeish, Dr Professor Rodney Reznek, Dr Norbert Avril, Dr Subham Basu, Dr Dan Berney,

    Dr Claude Chelala, Dr Tatjana Crnogorac-Jurcevic, Dr Gunnel Hallden, Dr Yong-Jie Lu, Dr Daniel

    Oberg, Dr David Prowse, Dr Rebecca Roylance, Dr Peter Szlosarek, Dr Yaohe Wang)

    ? Experimental Cancer Medicine (Professor John Gribben, Professor Iain McNeish, Dr Heather

    Oakervee, Dr Jonathan Shamash, Dr Thomas Powles, Dr Simon Joel)

    ? Medical Oncology (Professor Andrew Lister, Professor John Gribben, Professor Bryan Young,

    Professor Ama Rohatiner, Professor Finbarr Cotter, Dr Rebecca Auer, Dr Jude Fitzgibbon, Dr

    Silvia Montoto, Dr David Taussig)

    ? Tumour Biology (Professor Ian Hart, Professor Louise Jones, Professor Helen Hurst, Dr John

    Marshall, Dr Kairbaan Hodivala-Dilke, Dr Hemant Kocher, Dr Richard Grose, Dr Stephanie


    ? Cancer & Inflammation (Professor Fran Balkwill, Dr Thorsten Hagemann) ? Cancer Cell Signalling (Professor Bart Vanhaesebroeck, Dr Pedro Cutillas)

Prostate and other Male Genitourinary Cancer Research:

    Dr Thomas Powles is a Senior Lecturer in Medical Oncology who has focused his research on the efficacy of tyrosine kinase inhibitors in urology cancers. Clinical studies with lapatinib, sunitinib and

    axitinib are underway or planned. Much of his current work focuses on comparing sequential cancer

    tissue (or cancer cells isolated from the blood) before and after sunitinib therapy. It is hoped that this

    work will give us insight into the mechanisms of resistance to these drugs, and ultimately which

    patients benefit from them. He has also investigated novel treatments for testis cancer and the long-

    term side effects associated with them. The studies are run within the Orchid-sponsored Urology

    Cancer Clinical Trials Team in the Centre for Experimental Cancer Medicine. Dr Powles is involved in

    a number of research groups in urology cancer including the NCRN, EORTC and the Transatlantic

    Bladder Cancer Consortium. These groups have resulted in research collaborations and writing of

    guidelines for specific cancers.

    Dr Jonathan Shamash is a Consultant Medical Oncologist with a special interest in the treatment of genitourinary cancer, and particularly relapsed testicular cancer. His clinical trials continue apace,

    including a CTAAC-funded, multi-centre NCRN study of bleomycin infusion within BEP in patients

    with good risk but advanced testicular teratoma and a study of single agent carboplatin (AUC10) in

    patients with good risk metastatic seminoma.

    Dr Dan Berney is a consultant histopathologist and the focus of his research is the development of

    biomarkers in prostate, penile and testicular cancers, using tissue micro-arrays to create high-

    throughput assays. In prostate cancer the focus is the biological examination of a unique cohort of

    over 2000 prostate cancers treated conservatively in the 1990s, together with the Trans-Atlantic

    Prostate Group in collaboration with Prof Jack Cuzick in the Centre for Mathematics, Statistics and

    Epidemiology at Charterhouse Square. This cohort has already been the focus of numerous papers,

    and in 2008 Dr Berney was awarded a CRUK Translational grant for further research into the biopsy


specimens of this cohort. In testis cancer, Dr Berney in the custodian of the British Testicular Tumour

    Panel collection, which is the focus of ongoing studies, as well as providing pathological support for

    clinical trials, and work on the pathogenetic pathways of testicular cancer. In penile cancer, with the

    support of a grant from The Jean Shanks Foundation, Dr Berney has created a tissue microarray of

    this rare cancer to study penile cancer pathogenesis in relation to HPV infection.

    Dr. Gunnel Halldén‟s research programme is focused on the development of novel treatment

    strategies to target late stage androgen-independent prostate cancers using replication-selective

    oncolytic adenoviral mutants. The aims of the research are:

    ? To construct new viruses containing a combination of deletions, mutations, heterologous

    promoters and transgenes for optimal efficacy and therapeutic index while decreasing virus

    induced toxicity.

    ? To determine mechanisms and treatment regimens for synergistic interactions of viral

    mutants with current therapies such as cytotoxic drugs, cytokines and radiation therapy.

    ? To investigate cellular mechanisms of combination therapies to enhance tumour specific viral

    uptake, replication and cell death.

    ? To explore anti-tumour efficacy of targeted inhibition of constitutively active androgen

    receptors in late stage prostate cancers.

The overall goal of the team is to develop improved therapies for late stage, currently treatment-

    resistant prostate cancers, by constructing potent tumour specific oncolytic viruses to be evaluated in

    clinical trials together with other cytotoxic therapies.

    Dr Yong-Jie Lu‟s team undertakes translational research using molecular cytogenetics and

    genomics to identify targets for diagnosis and therapies of urological cancer. Dr Lu has set up a

    research programme of systematic genetic studies of prostate cancers and testicular germ cell

    tumours (TGCT). The mission of the research team is to identify, using a systematic approach,

    genomic alterations and genes significance influence the development, progression and therapeutic

    response of male urogenital tumours. These genetic alterations will be assessed as useful markers

    of tumour behaviour and potential targets for novel therapies. Discovering the genetic basis of drug

    sensitivity of TGCT may also lead to a wider understanding of the mechanisms of chemoresistance

    of other human cancers. There are currently three main research areas of interest:

    ? Identification of critical genes in the development and progression of prostate cancer and

    TGCTs using a genome-wide analysis approach.

    ? Investigation of the mechanism and consequence of genomic alterations, particularly

    rearrangements and translocations, in prostate cancer development.

    ? Investigation of the molecular and genetic mechanisms of chemoresistance of TGCTs. Dr David Prowse‟s main interest is to understand and target the molecular events involved in the

    development and progression of prostate and penile cancer. In particular, current studies focus on

    the identification and functional analysis of prostate and penile cancer biomarkers, the development

    and treatment of androgen independent prostate cancer, the role of prostate cancer cells with stem

    cell characteristics and the analysis of prostate circulating tumour cells enabling non-invasive

    diagnosis and monitoring of clinical trial patients. These approaches have significant potential for

    improving survival and quality of life for men's cancer patients.

Experimental Cancer Medicine:

    This Centre is headed by Professors John Gribben and Nick Lemoine. It was set up as part of a joint

    initiative between the Department of Health and Cancer Research UK to establish a network of

    centres dedicated to rapidly translating preclinical work through early phase clinical trials and

    eventually into treatment.

    The CECM at the SMD and Barts and The London NHS Trust is closely affiliated with the National

    Cancer Research Network, also directed by Prof John Gribben and thus incorporates Phase I

    through Phase IV clinical trials.

    The centre provides management support for all trials and investigators including national,

    pharmaceutical and investigator-led studies and centralises all staff involved in clinical trials to ensure compliance with the European Directive on Good Clinical Practice.

    The aims of the Centre are:

     * To increase recruitment into existing clinical trials.

     * To increase the number of trials NCRN, pharma-sponsored and investigator-initiated.

     * To increase the diversity of clinical trials open at Barts and The London NHS Trust.


Report this document

For any questions or suggestions please email